AstraZeneca: new US approval for Fasenra

(CercleFinance.com) - On Wednesday AstraZeneca announced that the US FDA has approved Fasenra for the treatment of eosinophilic granulomatosis with polyangiitis in adults.


Eosinophilic granulomatosis with polyangiitis is an organ-damaging inflammation of the blood vessels, often in patients with a history of asthma.

It is characterised by an increase in the number of eosinophils, a type of white blood cell that is an integral part of the immune system, leading to inflammation of the body.

If left untreated, this condition can sometimes prove fatal.

Already approved for the treatment of asthma, Fasenra is a monoclonal antibody that recruits natural killer cells, resulting in direct, rapid and almost total depletion of eosinophils.


Copyright (c) 2024 CercleFinance.com. All rights reserved.